Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

In vitro activity of plazomicin and other aminoglycosides against Klebsiella pneumoniae multidrug-resistant strains


Plazomicin is a new aminoglycoside with broad-spectrum activity against multidrug-resistant strains. The aim of this study was to assess the susceptibility of the K. pneumoniae strains to plazomicin and other aminoglycosides. The activity of plazomicin in combination with ceftazidim-avibactam or meropenem with selected strains was evaluated. The study involved 60 ESβL-positive K. pneumoniae isolates and 50 carbapenemase-positive. The susceptibility to aminoglycosides was tested using the gradient strip. The in vitro activities of plazomicin and ceftazidim-avibactam or meropenem were evaluated using the MTSTM cross synergy method. Plazomicin exhibited high activity against K. pneumoniae with MICs ranging from 0.19 to 4 µg ml−1 for ESβL-positive strains and from 0.25 to 256 µg ml−1 for carbapenemase-positive strains. No antagonism was identified with any combinations. Plazomicin demonstrated excellent in vitro activity against analyzed strains, suggesting that this antibiotic may be an effective therapeutic option in the treatment of infections caused by MDR K. pneumoniae strains.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: An Overview. Cold Spring Harb Perspect Med. 2016;6:a027029.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Alfieri A, Di Franco S, Donatiello V, Maffei V, Fittipaldi C, Fiore M, et al. Plazomicin against Multidrug-Resistant Bacteria: A Scoping Review. Life. 2022;12:1949.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Serio AW, Keepers T, Krause KM. Plazomicin Is Active Against Metallo-β-Lactamase-Producing Enterobacteriaceae. Open Forum Infect Dis. 2019;6:ofz123.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Blanchard LS, Van Belkum A, Dechaume D, Armstrong TP, Emery CL, Ying YX, et al. Multicenter Clinical Evaluation of ETEST Plazomicin (PLZ) for Susceptibility Testing of Enterobacterales. Ledeboer NA. J Clin Microbiol. 2022;60:e01831–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. EUCAST Clinical breakpoints and dosing of antibiotics. 2023. Available at: Assessed 3 October 2023.

  6. Clark JA, Burgess DS. Plazomicin: a New Aminoglycoside in the Fight Against Antimicrobial Resistance. Ther Adv Infect Dis. 2020;7:2049936120952604.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Wareham DW, Bean DC. In Vitro Activities of Polymyxin B, Imipenem, and Rifampin against Multidrug-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2006;50:825–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Data from the ECDC Surveillance Atlas - Antimicrobial Resistance. 2017. Available at:

  9. Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015. Antimicrob Agents Chemother. 2018;62:e02125–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Castanheira M, Sader HS, Mendes RE, Jones RN. Activity of Plazomicin Tested against Enterobacterales Isolates Collected from U.S. Hospitals in 2016-2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides. Antimicrob Agents Chemother. 2020;64:e02418–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Castanheira M, Deshpande LM, Woosley LN, Serio AW, Krause KM, Flamm RK. Activity of Plazomicin Compared with Other Aminoglycosides against Isolates from European and Adjacent Countries, including Enterobacteriaceae Molecularly Characterized for Aminoglycoside-Modifying Enzymes and other Resistance Mechanisms. J Antimicrob Chemother. 2018;73:3346–54.

    CAS  PubMed  Google Scholar 

  12. Saravolatz LD, Stein GE. Plazomicin: A New Aminoglycoside. Clin Infect Dis. 2020;70:704–9.

    CAS  PubMed  Google Scholar 

  13. Zhang Y, Kashikar A, Bush K. In Vitro Activity of Plazomicin against β-Lactamase-Producing Carbapenem-Resistant Enterobacteriaceae (CRE). J Antimicrob Chemother. 2017;72:2792–5.

    Article  CAS  PubMed  Google Scholar 

  14. Galani I, Papoutsaki V, Karantani I, Karaiskos I, Galani L, Adamou P, et al. In Vitro Activity of Ceftolozane/Tazobactam Alone and in Combination with Amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece. J Antimicrob Chemother. 2020;75:2164–72.

    CAS  PubMed  Google Scholar 

  15. Jacobs MR, Good CE, Hujer AM, Abdelhamed AM, Rhoads DD, Hujer KM, et al. ARGONAUT II Study of the In Vitro Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64:e00012–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Fleischmann WA, Greenwood-Quaintance KE, Patel R. In Vitro Activity of Plazomicin Compared to Amikacin, Gentamicin, and Tobramycin against Multidrug-Resistant Aerobic Gram-Negative Bacilli. Antimicrob Agents Chemother. 2020;64:e01711–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Martins AF, Bail L, Ito CAS, da Silva Nogueira K, Dalmolin TV, Martins AS, et al. Antimicrobial Activity of Plazomicin against Enterobacteriaceae-Producing Carbapenemases from 50 Brazilian Medical Centers. Diagn Microbiol Infect Dis. 2018;90:228–32.

    Article  CAS  PubMed  Google Scholar 

  18. Thwaites M, Hall D, Stoneburner A, Shinabarger D, Serio AW, Krause KM, et al. Activity of Plazomicin in Combination with other Antibiotics against Multidrug-Resistant Enterobacteriaceae. Diagn Microbiol Infect Dis. 2018;92:338–45.

    Article  CAS  PubMed  Google Scholar 

  19. Rodríguez-Avial I, Pena I, Picazo JJ, Rodríguez-Avial C, Culebras E. In vitro Activity of the Next-Generation Aminoglycoside Plazomicin Alone and in Combination with Colistin, Meropenem, Fosfomycin or Tigecycline against Carbapenemase-Producing Enterobacteriaceae Strains. Int J Antimicrob Agents. 2015;46:616–21.

    Article  PubMed  Google Scholar 

Download references


This research was financially supported by Nicolaus Copernicus University funds for the basic research activity of the Microbiology Department Ludwik Rydygier Collegium Medicum in Bydgoszcz, Poland.

Author information

Authors and Affiliations



AS: conceptualization, methodology, investigation, formal analysis, original draft, resources.

Corresponding author

Correspondence to Alicja Sękowska.

Ethics declarations

Conflict of interest

The author declares no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sękowska, A. In vitro activity of plazomicin and other aminoglycosides against Klebsiella pneumoniae multidrug-resistant strains. J Antibiot (2024).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI:


Quick links